Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2021-09-01 Environmental & Social …
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad anuncia la aprobación de Zepzelca® (lurbinectedina) para el tratamiento del cáncer de pulmón microcítico metastásico en Emiratos Árabes Unidos
Environmental & Social Information Classification · 99% confidence The document is addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces that PharmaMar's partner, Immedica Pharma AB, has received marketing approval for Zepzelca® in the UAE. Crucially, the text states: 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia.' (A press release that will be distributed to the media regarding this news is attached.) Although the document contains substantial detail (8090 chars), its primary function, as framed by the regulatory filing header and the explicit mention of attaching the press release, is to serve as an official regulatory disclosure of material, non-public information to the market regulator. This structure—a formal notification to the regulator accompanied by the actual news release—is characteristic of a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such official disclosures not covered elsewhere.
2021-09-01 Spanish
La Sociedad informa de cambios en la composición de la Comisión de Nombramientos y Retribuciones y de Sostenibilidad, y en la Comisión de Auditoría, así como de la modificación del Reglamento del Cons
Board/Management Information Classification · 98% confidence The document is a formal communication dated July 29, 2021, addressed to the Comisión Nacional del Mercado de Valores (CNMV), the Spanish securities market regulator. The content details decisions made by the Board of Directors regarding changes in the composition of key committees (Appointments and Remuneration, and Audit Committee) and modifications to the Board's Regulations to comply with recent legislation (Ley 5/2021). This type of announcement, which reports significant internal governance and board structure changes, aligns best with the 'Board/Management Information' category, as it specifically details appointments and changes in director roles and committee structures. It is not a general earnings release (ER), a full annual report (10-K), or a proxy statement (PSI). The document explicitly reports management/board actions, fitting the MANG definition.
2021-07-29 Spanish
El COMP de la EMA, ha dado su opinión positiva para designación de Medicamento Huérfano de Zepzelca® (lurbinectedina) para el tratamiento de mesotelioma
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) regarding the Orphan Drug Designation for Zepzelca® (lurbinectedin) for mesothelioma treatment. Crucially, the text states: 'Se adjunta nota de prensa que se distribuirá a los medios de comunicación en relación con esta noticia.' (A press release that will be distributed to the media regarding this news is attached.) This structure—a brief regulatory filing announcing attached press material—fits the definition of a Report Publication Announcement (RPA) or, if it's a general regulatory disclosure without a specific category, RNS. Since this is a specific, material, non-financial announcement (EMA opinion), and it explicitly mentions attaching a press release, it is best classified as an RPA, as it announces the publication/release of related information (the press release). If it were the full press release itself, it might lean towards ER or LTR (if regulatory), but the framing suggests a notification *about* the release.
2021-07-28 Spanish
La Sociedad anuncia la suscripción de un contrato de liquidez con JB Capital Markets, Sociedad de Valores, S.A.U.
Regulatory Filings Classification · 99% confidence The document is a formal communication dated July 13, 2021, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The content explicitly announces the subscription of a 'contrato de liquidez' (liquidity contract) with a financial intermediary, detailing the number of shares and cash involved, and referencing specific Spanish regulations (Article 227 of the Securities Market Law and CNMV Circular 1/2017). This type of announcement, concerning market operations, financing arrangements, or capital structure management, fits best under the 'Capital/Financing Update' category (CAP). While it involves shares, it is not a general share issue (SHA) or a buyback report (POS), but rather a specific agreement to manage market liquidity, which is a financing/capital market activity.
2021-07-13 Spanish
La Sociedad comunica la terminación del contrato de liquidez suscrito con fecha 4 de junio de 2018 con JB Capital Markets, Sociedad de Valores, S.A.U.
Transaction in Own Shares Classification · 98% confidence The document is a formal communication dated June 25, 2021, addressed to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores - CNMV). The content explicitly states that the company is terminating a liquidity contract ('contrato de liquidez') and provides detailed transaction records (purchases and sales of own shares) executed under that contract during Q2 2021. The termination of a liquidity contract, which involves the company buying back or selling its own shares, directly relates to the management of treasury stock. The specific category for reporting the company's transaction in its own shares is 'Transaction in Own Shares' (POS). Although it involves reporting details, the core subject is the execution and termination of a share repurchase/liquidity agreement, making POS the most precise fit over a general regulatory filing (RNS) or a general capital change (SHA).
2021-06-25 Spanish
La Sociedad publica información financiera correspondiente al primer trimestre de 2021.
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter (period ending March 31, 2021) of PharmaMar. It contains detailed financial statements, including income breakdowns, R&D expenditure, and balance sheet highlights. It is not merely an announcement of a report (RPA) because it provides substantive financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-05 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.